ImmunityBio, Inc. IBRX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$351.47M+15.0% | -$413.65M+29.2% | -$583.85M-39.9% | -$417.32M-19.3% | ||
| $15.53M-11.6% | $17.55M-5.2% | $18.51M+1.4% | $18.26M+28.2% | ||
| $36.81M+6.9% | $34.43M-30.0% | $49.16M+22.4% | $40.18M-29.7% | ||
| $40.21M— | —— | —— | $0— | ||
| $6.33M-23.5% | $8.27M— | —— | $0— | ||
| —— | -$3.17M+51.1% | -$6.48M-181% | $8M+315% | ||
| $3.18M— | —— | —— | —— | ||
| —— | $1.11M+163% | -$1.76M+17.5% | -$2.14M— | ||
| $570K— | —— | —— | —— | ||
| $0+100% | -$632K+60.3% | -$1.59M+64.3% | -$4.46M+3.4% | ||
| —— | $5.76M-5.8% | $6.11M+3.0% | $5.93M+21.5% | ||
| —— | -$5.47M-72.8% | -$3.17M+26.6% | -$4.32M-3.7% | ||
| -$304.94M+22.1% | -$391.24M-6.7% | -$366.76M-8.7% | -$337.51M-23.0% | ||
| $3.85M-44.2% | $6.89M-77.5% | $30.58M-60.9% | $78.16M+133% | ||
| $241.37M+72.1% | $140.22M+1,254% | $10.36M— | —— | ||
| —— | $115.59M+1,044% | $10.1M-92.1% | $128.19M+128% | ||
| —— | —— | -$32.72M— | —— | ||
| —— | $0— | $0— | —— | ||
| —— | $0— | $0— | —— | ||
| —— | —— | —— | $60.43M-63.3% | ||
| $28K-56.3% | $64K-16.9% | $77K+32.8% | $58K— | ||
| $2.27M-58.6% | $5.47M+58.7% | $3.44M+459% | $616K-84.8% | ||
| $400.24M+42.1% | $281.63M-49.6% | $558.34M+139% | $233.61M-53.8% | ||
| —— | —— | -$292K-203% | $284K— | ||
| —— | —— | $160.82M— | —— | ||
| $71.32M-22.7% | $92.32M+19.6% | $77.19M+118% | $35.44M+1,583% | ||
| $2.75M+84.4% | $1.49M+987% | $137K— | —— | ||
| —— | —— | $0— | $0— | ||
| —— | -$3.17M+51.1% | -$6.48M-181% | $8M+315% | ||
| —— | $763K— | —— | —— | ||
| $3.18M— | —— | —— | —— | ||
| $41.23M+8.5% | $38M— | —— | $0— | ||
| $250K+122% | -$1.15M+87.2% | -$8.99M+23.5% | -$11.75M— | ||
| —— | —— | —— | —— | ||
| $14.02M— | $0— | $0-100% | $1.33M— | ||
| —— | —— | —— | —— | ||
| —— | $747K— | —— | $0— | ||
| —— | —— | $0— | —— | ||
| —— | $115.59M+1,044% | $10.1M-92.1% | $128.19M+128% | ||
| $28K-56.3% | $64K-16.9% | $77K+32.8% | $58K— | ||
| —— | $0-100% | $258.7M+48.6% | $174.13M— | ||
| —— | $0— | $0— | —— | ||
| $0-100% | $73.28M— | $0— | $0— | ||
| —— | $0— | $0— | —— | ||
| —— | —— | —— | $13.68M— | ||
| $0— | $0-100% | $2.04M— | $0— | ||
| —— | —— | —— | —— | ||
| —— | —— | -$292K-203% | $284K— | ||
| $0— | $0-100% | $31.18M— | $0— | ||
| -$49.09M-146% | -$19.96M-142% | $47.6M+454% | -$13.46M— | ||
| $0— | $0-100% | $4.2M— | $0— | ||
| $0-100% | $96.96M— | —— | $0— | ||
| $0— | $0-100% | $3.78M— | $0— | ||
| $5.9M— | —— | $0-100% | $15M-35.0% | ||
| —— | —— | —— | $10.66M— | ||
| $293K-63.6% | $805K— | —— | $277K— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| -$308.78M+22.4% | -$398.12M-0.2% | -$397.34M+4.4% | -$415.67M-35.0% | ||
| -$308.78M+22.4% | -$398.12M-0.2% | -$397.34M+4.4% | -$415.67M-35.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ImmunityBio, Inc. generate?
- ImmunityBio, Inc. (IBRX) generated -$294.4M in operating cash flow over the trailing twelve months.
- What is ImmunityBio, Inc.'s free cash flow?
- After $4.5M of capital expenditures, ImmunityBio, Inc.'s free cash flow was -$298.9M over the trailing twelve months, up 20.7% year over year.
- Where does ImmunityBio, Inc.'s cash flow data come from?
- Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
